OTCMKTS:PRTX

Protalex Stock Forecast, Price & News

$0.01
0.00 (0.00 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.04
52-Week Range
$0.00
$0.10
VolumeN/A
Average Volume15,694 shs
Market Capitalization$615,290.00
P/E RatioN/A
Dividend YieldN/A
Beta-6.15
30 days | 90 days | 365 days | Advanced Chart
Receive PRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalex and its competitors with MarketBeat's FREE daily newsletter.


Protalex logo

About Protalex

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.85 out of 5 stars

Medical Sector

1215th out of 2,101 stocks

Commercial Physical Research Industry

16th out of 37 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Protalex (OTCMKTS:PRTX) Frequently Asked Questions

What stocks does MarketBeat like better than Protalex?

Wall Street analysts have given Protalex a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Protalex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Protalex's earnings last quarter?

Protalex, Inc. (OTCMKTS:PRTX) posted its quarterly earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share for the quarter.
View Protalex's earnings history
.

How has Protalex's stock price been impacted by COVID-19 (Coronavirus)?

Protalex's stock was trading at $0.0025 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRTX shares have increased by 420.0% and is now trading at $0.0130.
View which stocks have been most impacted by COVID-19
.

Who are Protalex's key executives?

Protalex's management team includes the following people:
  • Mr. Arnold P. Kling Esq., Pres & Director (Age 63, Pay $72k)
  • Dr. William E. Gannon Jr., Chief Medical Officer & Member of Scientific Advisory Board
  • Dr. John Bruce Lundy McClain M.D., Medical Director & Member of Scientific Advisory Board
  • Dr. Michelle Catalina Ph.D., Director of Preclinical Studies & Member of Scientific Advisory Board

Who are some of Protalex's key competitors?

What other stocks do shareholders of Protalex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalex investors own include The Boeing (BA), Caterpillar (CAT), salesforce.com (CRM), Enterprise Products Partners (EPD), Eros STX Global (EROS), Global Payments (GPN), Intuitive Surgical (ISRG), NVIDIA (NVDA), AT&T (T) and VirTra (VTSI).

What is Protalex's stock symbol?

Protalex trades on the OTCMKTS under the ticker symbol "PRTX."

How do I buy shares of Protalex?

Shares of PRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protalex's stock price today?

One share of PRTX stock can currently be purchased for approximately $0.01.

How much money does Protalex make?

Protalex has a market capitalization of $615,290.00.

How many employees does Protalex have?

Protalex employs 2 workers across the globe.

What is Protalex's official website?

The official website for Protalex is www.protalex.com.

Where are Protalex's headquarters?

Protalex is headquartered at 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932.

How can I contact Protalex?

Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The company can be reached via phone at 215-862-9720 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.